Future progress in mechanism-based cancer prevention research may be facilitated by animal models displaying specific genetic susceptibilities for cancer, such as mice defi cient in 1 (+/-) or both (-/-) alleles of the p53 tumor suppressor gene. We observed in p53-/- mice that calorie restriction (CR) increased the latency of spontaneous tumor development (mostly lymphomas) by approximately 75%, decreased serum insulin-like growth factor-1 (IGF-1) and leptin levels, slowed thymocyte cell cycle traverse, and induced apoptosis in immature thymocytes. In p53+/- mice, CR and a 1 d/wk fast each delayed spontaneous tumor development (a mix of lymphomas, sarcomas, and epithelial tumors) and decreased serum IGF-1 and leptin levels, even when begun late in life. In p53+/- Wnt-1 transgenic mice, a mammary tumor model, the same interventions increased mammary tumor latency and reduced mean serum IGF-1 and leptin levels to <50 % of those of control mice. We capitalized on the susceptibility of p53+/- mice to chronic, low-dose aromatic amine—induced bladder carcinogenesis to develop a useful model for evaluating bladder cancer prevention approaches. These examples clearly indicate that mice with specific (and humanlike) genetic susceptibilities for cancer are powerful models for testing interventions that may inhibit carcinogenesis in humans.
Chan JM, Stampfer MJ, Giovannucci E., Gann PH, Ma J., Wilkinson P., Hennekens CH, Pollak M. (1998). Plasma insulin-like growth factor-1 and prostate cancer risk: A prospective study. Science279: 563—566.
2.
DiGiovanni J. , Kiguchi K., Frijhoff A., Wilker E., Bol DK, Beltrán L., Moats S., Ramirez A., Jorcano J., Conti C. (2000). Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA97: 3455—3460.
3.
Donehower LA , Harvey M., Slagle BL, McArthur MJ, Montgomery CA, Butel J., Bradley A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature356: 215—221.
4.
Dunn SE, Kari FW, French J., Leininger JR, Travlos G., Wilson R., Barrett JC (1997). Dietary restriction reduces insulin-like growth factor-1 levels which modulates apoptosis, cell proliferation, and tumor progression in p53 deficient mice. Cancer Res57: 4667 — 4672.
5.
Fearon ER, Vogelstein B. (1990). A genetic model of human colorectal tumorigenesis . Cell61: 759—767.
Harvey M., McArthur MJ, Montgomery CA, et al (1993). Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet4: 225—229.
8.
Hollstein M. , Sidransky D., Vogelstein B., Harris CC (1991). p53 mutations in human cancers. Science253: 49—53.
9.
Huggins CB (1987). Selective induction of hormone-dependent mammary adenocarcinomas in the rat. J Lab Clin Med109: 262 — 266.
10.
Hursting SD , Kari FW (1999).The anti-carcinogenic effects of dietary restriction: Mechanisms and future directions. Mutat Res443: 235—249.
11.
Hursting SD , Perkins SN, Brown CC, Haines DC, Phang JM (1997). Calorie restriction induces a p53-independent delay of spontaneous carcinogenesis in p53-deficient and wild-type mice. Cancer Res57: 2843—2846.
12.
Hursting SD , Perkins SN, Donehower LA, Fuchs-Young, R., Clinton S., Baum L., DeLa Cerda J., Davis BJ (2000). Chemoprevention of spontaneous mammary tumorigenesis in p53-deficient Wnt-1 transgenic mice. Proc Am Assoc Cancer Res41: A528.
Hursting SD , Perkins SN, Ward J., Haines D., Phang JM (1995). Chemoprevention of spontaneous tumorigenesis in p53-knockout mice. Cancer Res55: 3949—3953.
15.
Hursting S. , Purewal M., Woods C., Velasco M., Wargovich M. (1998). Chemoprevention of azoxymethane-induced aberrant crypt foci and colon tumors in p53-deficient mice by sulindac. Cancer Epidemiol Biol Prev7: 176.
16.
Hursting SD , Slaga TJ, Fischer SM, DiGiovanni J., Phang JM (1999). Mechanism-based cancer prevention approaches: Targets, examples and the use of transgenic mice. J Natl Cancer Inst91: 215—225.
17.
Hursting SD , Switzer BR, French JE, Kari FW (1993). The growth hormone: Insulin-like growth factor 1 axis is a mediator of diet restriction-induced inhibition of mononuclear cell leukemia in Fischer rats . Cancer Res53: 2750—2757.
18.
Jones JM, Attardi L., Godley LA, Laucirica R., Medina D., Jacks T., Varmus HE, Donehower LA (1997). Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ8: 829—838.
19.
Kasper S., Sheppard PC, Yan Y., Pettigrew N., Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ (1998). Development, progression and androgen dependence of prostate tumors in probasin large T antigen transgenic mice: A model for prostate cancer. Lab Invest78: 319—333.
20.
Kemp CJ, Donehower LA, Bradley A., Balmain A. (1993). Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell74: 813—822.
21.
Kemp CJ, Wheldon T., Balmain A (1994). p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet8: 66—69.
22.
Lavigueur A. , Maltby V., Mock D., Rossant J., Pawson T., Bernstein A. (1989). High incidence of lung, bone and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol9: 3982—3991.
23.
Loffreda S., Yang SQ, Lin HZ, et al (1998). Leptin regulates proinflammatory immune responses. FASEB J12: 57—65.
24.
Lord GM, Matarese G., Howard JK, Baker RJ, Bloom SR, Lechler RI (1998). Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature394: 897— 901.
25.
Lubet RA, Fischer SM, Conti C., Kelloff GJ, Zhang Z., You M. (2000). Chemopreventive effi cacy of NSAIDs in tumor models with mutations in the p53 tumor suppressor gene. Proc Am Assoc Cancer Res41: A2617.
26.
Mei JM, Hursting SD, Perkins SN, Phang JM (1998).p53-independent inhibition of nitric oxide generation by cancer preventive interventions in ex vivo mouse peritoneal macrophages. Cancer Lett129: 191—197.
27.
Perkins SN, Davis BJ, Donehower LA, DeLa Cerda J., Baum L., Hursting SD (2000). Effects of dietary restriction on spontaneous mammary tumorigenesis in p53-deficient Wnt-1 transgenic mice. Proc Am Assoc Cancer Res41: A531.
28.
Perkins SN, Hursting SD, Haines DC, James SJ, Phang JM (1997). Chemoprevention of spontaneous tumorigenesis in nullizygous p53-deficient mice by dehydroepiandro-sterone and its analog, 16-fluoro-5-androsten-17-one. Carcinogenesis18: 101—106.
29.
Pitot HC (1989). Progression: The terminal stage in carcinogenesis . Jpn J Cancer Res80: 599—607.
30.
Poetschke HL , Klug DB, Perkins SN, Wang TTY, Richie ER, Hursting SD (2000). The effects of calorie restriction on thymocyte growth, death and maturation . Carcinogenesis21: 1959 —1964.
31.
Schwartz AG , Pashko LL (1995). Mechanism of cancer preventive action of DHEA. Role of glucose 6-phosphate dehydrogenase . Ann NY Acad Sci774: 180—186.
32.
Shibata M., Ward JM, Devor DE, Liu M., Green JE (1996). Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: Histopathological and molecular biological alterations. Cancer Res56: 4894—4903.
Slaga TJ (1984). Mechanisms involved in two-stage carcinogenesis in mouse skin. In: Mechanisms of Tumor Promotion, Slaga TJ (ed). CRC Press, Boca Raton, Florida, pp 1—93.
35.
Stanley LA (1995). Molecular aspects of chemical carcinogenesis: The roles of oncogenes and tumor suppressor genes. Toxicology96: 173—194.
36.
Sugimura T. (1992). Multistep carcinogenesis: A 1992 perspective. Science258: 603—607.
37.
Tennant RW, French JE, Spalding JW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mice. Environ Health Perspect103: 942—950.
38.
Wang TTY , Hursting SD, Perkins SN, Phang JM (1997). Effects of dehydroepiandrosterone and calorie restriction on the Bcl-2/Baxmediated apoptotic pathway in p53-deficient mice . Cancer Lett116: 61—69.
39.
Wechter WJ, Leipold DD, Murray ED, Quiggle D., McCracken JD, Barrios RS, Greenberg NM (2000). E-7689 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res60: 2203—2208.
40.
Weindruch R, Walford RL (eds) (1988). The Retardation of Aging and Disease by Dietary Restriction. Charles C Thomas , Springfield, Illinois.
41.
Yuspa SH, Poirier MC (1988). Chemical carcinogenesis: From animal models to molecular models in one decade. Adv Cancer Res50: 25—70.
42.
Yuspa SH, Shields PG (1997). Etiology of cancer: Chemical factors. In: Cancer: Principles and Practices of Oncology, 5th ed, Devita VT, Hellman SH, Rosenberg SA (eds). Lippincott-Raven, Philadelphia , pp 185—202.
43.
Zhang Z., Lantry LE, Wang Y., Wiseman RW, Grubbs CH, Lubet RA, You M. (2000). Organ-specific effect of a germline p53 mutation on chemical carcinogenesis in mice: A new model for cancer intervention. Proc Am Assoc Cancer Res41: A2617.
44.
Zhang Z., Liu Q., Lantry LE, Wang Y., Kelloff GJ, Anderson MW, Wiseman RW, Lubet RA, You M. (2000). A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independnet effi cacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol and adriamycin . Cancer Res60: 901—907.
